TCRR - Radius Health Licensing Deal And Other News: The Good Bad And Ugly Of Biopharma
Radius Health inks licensing deal for elacestrant
Radius Health Inc. (RDUS) announced that it has inked an exclusive global license agreement with privately-held Menarini for developing and commercializing of elacestrant. The drug candidate is currently being assessed in a Phase 3 study as hormonal treatment for postmenopausal women and men with advanced ER+/HER2- breast cancer.
The terms of the agreement provide for an upfront payment of $30 million to Radius. Additionally, the company will also be entitled to receive up to $320 million in milestone payments based on meeting several targets. Kelly Martin,